CN109111403A - Horse former times rises smooth related substance, preparation method and the usage - Google Patents

Horse former times rises smooth related substance, preparation method and the usage Download PDF

Info

Publication number
CN109111403A
CN109111403A CN201810839815.7A CN201810839815A CN109111403A CN 109111403 A CN109111403 A CN 109111403A CN 201810839815 A CN201810839815 A CN 201810839815A CN 109111403 A CN109111403 A CN 109111403A
Authority
CN
China
Prior art keywords
former times
smooth
compound
horse former
horse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810839815.7A
Other languages
Chinese (zh)
Inventor
王留博
王足兵
林萍
吴晶
王华萍
柴雨柱
徐丹
朱春霞
田舟山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Original Assignee
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd filed Critical Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Priority to CN201810839815.7A priority Critical patent/CN109111403A/en
Publication of CN109111403A publication Critical patent/CN109111403A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses such as following formula (I) compound represented, it rises the purposes of smooth impurity reference substance as horse former times and separation determination horse former times rises smooth and formula (I) compound efficient liquid-phase chromatography method.Preparation method reaction condition provided by the invention is mild, post-processing is simple, and the satisfactory formula of purity (I) compound, the impurity reference substance to rise smooth quality analysis as horse former times can be gone out with prepare with scale.

Description

Horse former times rises smooth related substance, preparation method and the usage
Technical field
The invention belongs to pharmaceutical synthesis fields, and in particular to horse former times rises smooth related substance, preparation method and purposes.
Background technique
It is the dual endothelin receptor antagonist developed by Actelion that horse former times, which rises smooth, and FDA approval listing in 2013 is clinical Treatment for pulmonary hypertension.Its structural formula is as follows:
Carrying out quality control to bulk pharmaceutical chemicals and preparation is always the key points and difficulties in medicament research and development, and to miscellaneous Quality Research It is the most important thing in quality control again.Horse former times rises starting material, intermediate, by-product and catabolite in smooth synthesis process Deng being likely to become the impurity remained in finished product, and then influence product quality.
The smooth research in relation to object Quality Research and Analysis of quality control method is risen to horse former times at present and rarely has document report.
It is technique side reaction impurity and degradation impurity that Ma Xi, which rises smooth impurity H and impurity I, and synthesis and quality research are to work The quality of skill controls and stability study is of great significance.
Summary of the invention
The technical problem to be solved by the present invention is to rise issuable related substance in smooth synthesis process to horse former times to grind Study carefully.
The first aspect of the present invention provides lower formula (I) compound represented:
R is selected from H, Br;
When R is H, Compound nomenclature H, when R is Br, Compound nomenclature J.
The second aspect of the present invention provides above-mentioned formula (I) compounds process for production thereof:
(1) compound H's the preparation method is as follows:
Horse former times is risen into smooth generation debromination and generates compound H;
Preferably, debromination is in ammonium formate/Pd-C system or Pd-C/H2It is carried out under system;
Preferably, reaction dissolvent is selected from anhydrous C1~C4 alcohols solvent, more preferable anhydrous methanol, dehydrated alcohol.
(2) compound J's the preparation method is as follows:
1) debromination is occurred into for compound V and generates intermediate V-6;
2) intermediate V-6 reacts in the presence of alkaline reagent with the bromo- 2- chlorine pyrimidine of 5- generates compound J;
Preferably, in step (1) ammonium formate, Pd/C system under debromination occurs;
Preferably, reaction dissolvent is selected from anhydrous C1~C4 alcohols solvent, more preferable anhydrous methanol, anhydrous second in step (1) Alcohol;
Preferably, the alkaline reagent in step (2) is selected from sodium hydride, hydrofining, sodium tert-butoxide, potassium tert-butoxide, the tert-butyl alcohol Lithium;
Preferably, the reaction dissolvent of step (2) is selected from glycol dimethyl ether, tetrahydrofuran, toluene, N, N- dimethyl formyl Amine, dimethyl sulfoxide, one or both of more preferable tetrahydrofuran, n,N-Dimethylformamide.
Third aspect present invention provides the purposes that formula (I) compound rises smooth bulk pharmaceutical chemicals impurity reference substance as horse former times.
Fourth aspect present invention provide a kind of separation determination horse former times rise it is smooth with formula (I) compound high performance liquid chromatography side Method, comprising the following steps:
Chromatographic condition setting: using octadecylsilane chemically bonded silica as chromatography column packing, with 8~12mmol/L di(2-ethylhexyl)phosphate Hydrogen aqueous solutions of potassium-acetonitrile is mobile phase A, using acetonitrile as Mobile phase B, carries out gradient elution;Wherein potassium dihydrogen phosphate aqueous solution is used It is 4.5~5.5 that sodium hydroxide, which adjusts pH,;
Solution is prepared: being risen smooth raw material using acetonitrile dissolution horse former times, is configured to the solution that concentration is 0.1~1mg/mL;
Detection: it takes the horse former times of preparation to rise smooth solution injection high performance liquid chromatograph, records chromatogram and analyzed.
Preferably, wherein the gradient elution program is as follows:
Beneficial effects of the present invention: the present invention rises issuable related substance in smooth synthesis process to horse former times and is ground Study carefully, compound H, compound J have been prepared by above-mentioned preparation method, it is miscellaneous in smooth bulk pharmaceutical chemicals quality research to be risen as horse former times Matter reference substance.The present invention also provides a kind of separation determination horse former times to rise smooth and high-efficient liquid phase color in relation to substance H and in relation to substance J Whether spectral analysis method can quickly detect containing related substance H and related substance J in bulk pharmaceutical chemicals, be qualitative and quantitative detection Horse former times rises smooth bulk pharmaceutical chemicals and provides new selection.
Specific embodiment
The present invention is further explained below, but is not intended to limit the present invention.
Horse former times rises smooth bulk pharmaceutical chemicals and is made by oneself by Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
Preparation of the embodiment 1 in relation to substance H
Weigh 3.0g horse former times rise it is smooth be added in single port bottle, 30ml dehydrated alcohol and 1.5gPd/C and 0.6g formic acid is added Ammonium, back flow reaction 4h, is down to room temperature, and reaction solution is poured into 300ml aqueous citric acid solution, stirs 2h, filters, and filtration cakes torrefaction obtains 1.6g solid.Crude product obtains 1.0g solid with recrystallizing methanol.HPLC purity 100%.1H NMR(DMSO-d6): δ 9.35 (1H, s), 8.57(2H,d),8.50(1H,s),7.37(3H,d),7.23(3H,d),7.13(1H,t),4.66(2H,s),4.57(2H,s), 2.81(2H,q),1.42(2H,m),0.80(3H,t).ESI(+)m/z 431.3
Preparation of the embodiment 2 in relation to substance H
Weigh 3.0g horse former times rise it is smooth be added in single port bottle, 30ml anhydrous methanol and 1.5g Pd/C is added, in hydrogen atmosphere Lower reaction 3h, is down to room temperature, and reaction solution is poured into 300ml aqueous citric acid solution, stirs 2h, filters, and filtration cakes torrefaction obtains 1.5g Solid.8ml methanol is added, flow back 2h, is down to room temperature, filters, and filtration cakes torrefaction obtains 0.8g solid, HPLC purity 99.5%.
Preparation of the embodiment 3 in relation to substance J
It takes 10.0g intermediate V, 5.1g ammonium formate, 5.0gPd/C and 100ml dehydrated alcohol to add in reaction flask, heats back 2h is flowed, is filtered, the elution of 20ml dehydrated alcohol.Filtrate is poured into 10% aqueous citric acid solution of 300ml, and 50ml ethyl acetate is added to extract It takes 3 times, organic phase is dry with 40.2g anhydrous magnesium sulfate, and suction filtration is concentrated to give solid, and solid adds 10ml anhydrous methanol, is heated to back Stream, is cooled to 20 DEG C of stirring and crystallizings, filters, and 5ml anhydrous methanol elution, filtration cakes torrefaction obtains 2.1g V -6.
0.7g sodium hydrogen, 21ml tetrahydrofuran and above-mentioned 2.1g V -6 are added into single port bottle, 5ml DMF is added after stirring 1h With the bromo- 2- chlorine pyrimidine of 1.4g5-, 60 DEG C are heated to, reacts 2h.25 DEG C are cooled to, filtrate is poured into 10% citric acid water of 60ml Solution, stirring are added 150ml ethyl acetate and extract 3 times, and organic addition 38.6g anhydrous magnesium sulfate is dry, filters, and organic phase is dense It is reduced to dry solid, adds 10ml anhydrous methanol to be heated to flowing back, is cooled to 12 DEG C of stirring and crystallizings, is filtered, filtration cakes torrefaction obtains 1.8g Solid, HPLC purity: 97.2%.1H NMR(DMSO-d6): δ 9.36 (1H, s), 8.69 (2H, s), 8.49 (1H, s), 7.35 (3H,m),7.22(3H,m),4.64(2H,m),4.57(2H,m),2.78(2H,q),1.41(2H,m),0.80(3H,t).ESI (+)m/z 509.3
Preparation of the embodiment 4 in relation to substance J
It takes 10.0g intermediate V, 5.1g ammonium formate, 5.0gPd/C and 100ml anhydrous methanol to add in reaction flask, heats back 2h is flowed, reaction solution directly filters, the elution of 20ml dehydrated alcohol.Filtrate is poured into 10% aqueous citric acid solution of 300ml, and 150ml is added Ethyl acetate extracts 3 times, and organic phase is dry with 40.2g anhydrous magnesium sulfate, and suction filtration is concentrated to give solid, and solid adds 10ml without water beetle Alcohol is heated to reflux dissolved clarification, is cooled to 20 DEG C of stirring and crystallizings, filters, and 5ml anhydrous methanol elution, filtration cakes torrefaction obtains 2.0g V -6.
0.8g sodium hydrogen, 21ml tetrahydrofuran and above-mentioned 2.0g V -6 are added into single port bottle, 5ml toluene is added after stirring 1h With the bromo- 2- chlorine pyrimidine of 1.4g5-, 60 DEG C are heated to, reacts 2h.25 DEG C are cooled to, filtrate is poured into 10% citric acid water of 60ml Solution stirring, adds 150ml ethyl acetate to extract 3 times, and organic addition 38.6g anhydrous magnesium sulfate is dry, filters, and organic phase is concentrated into Solid is done to obtain, 10ml anhydrous methanol is added to be heated to reflux, is cooled to 12 DEG C, stirring and crystallizing filters, and filtration cakes torrefaction obtains 2.1g solid.
5 analysis method of embodiment
Instrument: 1100/1260 high performance liquid chromatograph of Agilent
Chromatographic column: YMC-Pack ODS-A (250 × 4.6mm, 5 μm)
Mobile phase: 10mmol/L potassium dihydrogen phosphate (it is 5.0 that sodium hydroxide solution, which adjusts pH)-acetonitrile (90:10) is flowing Phase A;Using acetonitrile as Mobile phase B, according to the form below carries out linear gradient elution:
Detection wavelength: 210nm
Flow velocity: 1mL/min
Column temperature: 30 DEG C
Sample volume: 10 μ L
Related substance H prepared in the above embodiments, appropriate J are taken respectively, it is accurately weighed, it acetonitrile is added dissolves and dilutes and is made Solution of every 1mL containing about 0.5mg is as positioning solution.
Weighing horse former times rises smooth appropriate, and impurity H, J is added and positions solution, is made former times containing horse in every 1mL and rises smooth about 0.5mg, divides The solution of not impure about 2.5 μ g of H, J, as system suitability solution.
Weighing horse former times rises smooth appropriate, is placed in measuring bottle, uses acetonitrile dissolve and dilutes the solution of 0.5mg/mL is made as confession Test sample solution.
Measurement: impurity H, J positioning solution, system suitability solution, horse former times rise each 10 μ L of smooth test solution and are injected separately into High performance liquid chromatograph records chromatogram.The result shows that this method may be implemented to rise smooth good point in relation to substance H, J and horse former times Risen from, horse former times smooth in 25.805min appearance, related substance H is in 9.957min appearance, and related substance J is in 18.981min appearance. Test solution measurement result shows that horse former times made from our company rises in smooth bulk pharmaceutical chemicals without related substance H and related substance J.

Claims (10)

1. lower formula (I) compound represented:
R is selected from H, Br.
2. compound represented according to claim 1, which is characterized in that R H.
3. compound represented according to claim 1, which is characterized in that R Br.
4. the method for preparing compound described in claim 2, which is characterized in that synthetic route is as follows:
Horse former times is risen into smooth generation debromination prepare compound H.
5. the preparation method according to claim 4, which is characterized in that horse former times rises smooth in ammonium formate/Pd-C system or Pd-C/ H2Debromination prepare compound H occurs under system.
6. the method for preparing compound described in claim 3, which is characterized in that synthetic route is as follows:
Debromination is occurred into for compound V and generates intermediate V-6;
(1) intermediate V-6 reacts in the presence of alkaline reagent with the bromo- 2- chlorine pyrimidine of 5- generates compound J.
7. preparation method according to claim 6, which is characterized in that in ammonium formate/Pd-C system or Pd- in step (1) C/H2Debromination occurs under system;Alkaline reagent in step (2) is selected from sodium hydride, hydrofining, sodium tert-butoxide, the tert-butyl alcohol Potassium, tert-butyl alcohol lithium.
8. compound described in claim 1 is rising the purposes in smooth bulk pharmaceutical chemicals impurity reference substance as horse former times.
9. a kind of separation determination horse former times rises smooth and formula (I) compound efficient liquid-phase chromatography method, which is characterized in that including following Step:
Chromatographic condition setting: using octadecylsilane chemically bonded silica as chromatography column packing, with 8~12mmol/L potassium dihydrogen phosphate Aqueous solution-acetonitrile is mobile phase A, using acetonitrile as Mobile phase B, carries out gradient elution;Wherein potassium dihydrogen phosphate aqueous solution hydrogen-oxygen Changing sodium to adjust pH is 4.5~5.5;
Sample solution is prepared: being risen smooth raw material using acetonitrile dissolution horse former times, is configured to the solution that concentration is 0.1~1mg/mL;
Detection: it takes the horse former times of preparation to rise smooth solution injection high performance liquid chromatograph, records chromatogram and analyzed.
10. according to the method described in claim 9, it is characterized in that, gradient elution program is as follows:
CN201810839815.7A 2018-07-27 2018-07-27 Horse former times rises smooth related substance, preparation method and the usage Pending CN109111403A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810839815.7A CN109111403A (en) 2018-07-27 2018-07-27 Horse former times rises smooth related substance, preparation method and the usage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810839815.7A CN109111403A (en) 2018-07-27 2018-07-27 Horse former times rises smooth related substance, preparation method and the usage

Publications (1)

Publication Number Publication Date
CN109111403A true CN109111403A (en) 2019-01-01

Family

ID=64863685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810839815.7A Pending CN109111403A (en) 2018-07-27 2018-07-27 Horse former times rises smooth related substance, preparation method and the usage

Country Status (1)

Country Link
CN (1) CN109111403A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1095702A (en) * 1993-05-21 1994-11-30 中国科学院大连化学物理研究所 The reduction dehalogenation reaction of active alkali metal hydride halohydrocarbon under action
CN105388244A (en) * 2015-12-10 2016-03-09 合肥久诺医药科技有限公司 High performance liquid chromatography method of macitentan related substances
CN105461639A (en) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 Method for refining high-purity macitentan
CN106478520A (en) * 2016-10-11 2017-03-08 合肥久诺医药科技有限公司 A kind of synthetic method of ACT-064992 contamination levels product

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1095702A (en) * 1993-05-21 1994-11-30 中国科学院大连化学物理研究所 The reduction dehalogenation reaction of active alkali metal hydride halohydrocarbon under action
CN105388244A (en) * 2015-12-10 2016-03-09 合肥久诺医药科技有限公司 High performance liquid chromatography method of macitentan related substances
CN105461639A (en) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 Method for refining high-purity macitentan
CN106478520A (en) * 2016-10-11 2017-03-08 合肥久诺医药科技有限公司 A kind of synthetic method of ACT-064992 contamination levels product

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LIXIU YU ET AL.: "Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry", 《JOURNAL OF CHROMATOGRAPHY B》 *
MARTIN H. BOLLI ET AL.: "The Discovery of N‑ [5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]‑N′‑propylsulfamide(Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
RANDALL B. NELSON AND GORDON W. GRIBBLE: "Reduction of aryl iodides with sodium hydride", 《J. ORG. CHEM.》 *
SHELTON BANK AND MARY C. PRISLOPSKI: "The high reactivity of radical-anion-prepared sodium hydride: reaction with benzyl chloride", 《CHEMICAL COMMUNICATIONS》 *
施悦 等: "《环境氧化还原处理技术原理与应用》", 31 August 2013, 哈尔滨工业大学出版社 *
聂忠莉 等: "HPLC测定马西替坦中的有关物质", 《华西药学杂志》 *
顾翼东: "《化学词典》", 30 September 1989, 上海辞书出版社 *

Similar Documents

Publication Publication Date Title
CN112697912B (en) Method for detecting tofacitinib citrate intermediate and related impurities thereof
CN103864774B (en) A kind of preparation method of Lurasidone
CN112480013A (en) 3, 4-dihydropyrimidine benzonitrile derivative, and preparation method and application thereof
CN114644614B (en) Preparation method of levo-nicotine
CN101701942A (en) Method for separating and measuring entecavir and optical isomer thereof by liquid chromatography
CN109212044A (en) A kind of detection method of Austria's shellfish cholic acid in relation to substance
US9067965B2 (en) Preparation method of rocuronium
CN109608468A (en) Tofacitinib citrate impurity, and synthesis method and application thereof
CN109111403A (en) Horse former times rises smooth related substance, preparation method and the usage
CN107880063B (en) A kind of synthetic method of dauricine
CN109293682A (en) A kind of support method is for cloth impurity and preparation method thereof
EP2389354A1 (en) 2-{2-amino-3-ýhydroxy(phenyl)methyl¨phenyl} acetamide
CN109180666A (en) A kind of fumaric acid Lu pa is for fragrant impurity C and preparation method thereof and detection method
CN115232077A (en) Oxagolide sodium related substance and preparation method thereof
CN112321642A (en) Ruidexiwei related substance and preparation method and application thereof
CN107573291A (en) A kind of preparation method and purposes of Gadoxetic acid disodium part impurity
CN107089979B (en) A kind of synthesis technology of palonosetron Hcl hydrochloride
CN112358504A (en) Ruidexiwei related substance and preparation method and application thereof
CN108727279A (en) Horse former times rises smooth related substance D, preparation method and the usage
CN104892642A (en) Method for purifying vindesine
CN105503875B (en) A kind of synthetic method of TDF intermediate impurities
CN105001243A (en) Method for industrially preparing chromatographically pure vinorelbine
CN108732276B (en) High performance liquid chromatography analysis method for related substances of Mcjuxtant
CN112834643B (en) Method for measuring 2, 6-dihydroxy-4-methylpyridine and 2, 6-dihydroxy-3-cyano-4-methylpyridine
CN112480074A (en) 3, 4-dihydropyrimidine benzonitrile derivative, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190101